Skip to main content

Table 3 Association of CD44/CD24 immunophenotypes with clinicopathological variables in 69 SGMN patients

From: CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms

  

CD44/CD24 profilea

  

+/+

+/−

−/+

−/−

Total

p

Gender

Male

2 (2.9%)

17 (24.6%)

4 (5.8%)

5 (7.2%)

28 (40.6%)

0.091

 

Female

12 (17.4%)

19 (27.5%)

0 (0.0%)

10 (14.5%)

41 (59.4%)

 

Age

≤ 60

8 (11.6%)

22 (31.9%)

2 (2.9%)

9 (13.0%)

41 (59.4%)

0.967

 

> 60

6 (8.7%)

14 (20.3%)

2 (2.9%)

6 (8.7%)

28 (40.6%)

 

Smoking intake

Yes

3 (4.3%)

12 (17.4%)

2 (2.9%)

6 (8.7%)

23 (33.3%)

0.554

No

11 (15.9%)

24 (34.8%)

2 (2.9%)

9 (13.0%)

46 (66.7%)

 

Alcohol intake

Yes

2 (2.9%)

7 (10.1%)

3 (4.3%)

2 (2.9%)

14 (20.3%)

0.831

 

No

12 (17.4%)

29 (42.0%)

1 (1.4%)

14 (21.7%)

55 (79.7%)

 

PLSb

Majorc

7 (10.1%)

27 (39.1%)

4 (5.8%)

4 (5.8%)

42 (60.9%)

0,005

 

Minord

7 (10.1%)

9 (13.0%)

0 (0.0%)

11 (15.9%)

27 (39.1%)

 

Tumor size

T1/T2

4 (5.8%)

24 (34.8%)

3 (4.3%)

11 (15.9%)

42 (60.8%)

0.023

 

T3/T4

10 (14.5%)

12 (17.4%)

1 (1.4%)

4 (5.8%)

27 (39.1%)

 

Clinical Stage

I / II

2 (2.9%)

17 (24.6%)

0 (0.0%)

6 (8.7%)

25 (36.2%)

0.098

 

III / VI

12 (17.4%)

19 (27.5%)

4 (5.8%)

9 (13.0%)

44 (63.8%)

 

Treatment

Surgery

3 (4.3%)

11 (15.9%)

1 (1.4%)

4 (5.8%)

19 (27.5%)

0.807

 

Sur. Adj T.e

11 (15.9%)

25 (36.2%)

3 (4.3%)

11 (15.9%)

50 (72.5%)

 

Metastasis

No

8 (11.6%)

24 (34.8%)

2 (2.9%)

9 (13.0%)

43 (62.3%)

0.790

 

Yes

6 (8.7%)

12 (17.4%)

2 (2.9%)

6 (8.7%)

26 (37.7%)

 

Loco-regional

No

8 (11.6%)

25 (36.2%)

2 (2.9%)

10 (14.5%)

45 (65.2%)

0.711

Recurrence

Yes

6 (8.7%)

11 (15.9%)

2 (2.9%)

5 (7.2%)

24 (34.8%)

 

Lymph node

No

9 (13.0%)

34 (49.3%)

1 (1.4%)

14 (20.3%)

58 (84.0%)

0,011

 

Yes

5 (7.2%)

2 (2.9%)

3 (4.3%)

1 (1.4%)

11 (16.0%)

 

Death

No

11 (15.9%)

25 (36.2%)

3 (4.3%)

9 (13.0%)

48 (69.6%)

0.556

 

Yes

3 (4.3%)

11 (15.9%)

1 (1.4%)

6 (8.7%)

21 (30.4%)

 
  1. a +/+ cases CD44+/CD24+; +/− cases CD44+/CD24- and −/− cases CD44-/CD24-; −/− cases CD44-/CD24+. bPLS: Primary Lesion Site; cMajor: Major Salivary Glands ( Parotid Gland/Submandibular Gland/Sublingual Gland); dMinor; Minor Salivary Glands; eSur. Adj. T.: Surgery with adjuvant therapy. Statistically significant difference (<0.05) by Fisher’s exact test (two variables) or χ2 (three or more variables) tests.
Back to article page